Medical Care

Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Research Report 2024

Transthyretin Amyloidosis (ATTR) is a progressive and severe orphan disease. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a type of transthyretin amyloidosis (ATTR) that affects the heart and leads to restrictive cardiomyopathy and progressive heart failure. It is generally a rare, underdiagnosed, life-threatening disease.
The global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment.
Report Scope
The Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer Inc
GlaxoSmithKline Plc
Eidos Therapeutics
Ionis Pharmaceuticals, Inc
Alnylam Pharmaceuticals
Prothena Corporation Plc
Intellia Therapeutics, Inc
Corino Therapeutics, Inc
Segment by Type
Transthyretin Stabilizers
Nonsteroidal Anti-inflammatory Drugs (NSAID)
RNAi Therapy
Others
Segment by Application
Hereditary Transthyretin Amyloidosis (hATTR)
Wild Type Transthyretin Amyloidosis (wtATTR)
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Transthyretin Stabilizers
1.2.3 Nonsteroidal Anti-inflammatory Drugs (NSAID)
1.2.4 RNAi Therapy
1.2.5 Others
1.3 Market by Application
1.3.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hereditary Transthyretin Amyloidosis (hATTR)
1.3.3 Wild Type Transthyretin Amyloidosis (wtATTR)
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Perspective (2019-2030)
2.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Growth Trends by Region
2.2.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Historic Market Size by Region (2019-2024)
2.2.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Region (2025-2030)
2.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Dynamics
2.3.1 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Industry Trends
2.3.2 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Drivers
2.3.3 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Challenges
2.3.4 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Revenue
3.1.1 Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Revenue (2019-2024)
3.1.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue
3.4 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Concentration Ratio
3.4.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in 2023
3.5 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Key Players Head office and Area Served
3.6 Key Players Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Solution and Service
3.7 Date of Enter into Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Breakdown Data by Type
4.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Historic Market Size by Type (2019-2024)
4.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Type (2025-2030)
5 Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Breakdown Data by Application
5.1 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Historic Market Size by Application (2019-2024)
5.2 Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2019-2030)
6.2 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2019-2024)
6.4 North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2019-2030)
7.2 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2019-2024)
7.4 Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2019-2030)
8.2 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2019-2030)
9.2 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2019-2024)
9.4 Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (2019-2030)
10.2 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer Inc
11.1.1 Pfizer Inc Company Detail
11.1.2 Pfizer Inc Business Overview
11.1.3 Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.1.4 Pfizer Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2019-2024)
11.1.5 Pfizer Inc Recent Development
11.2 GlaxoSmithKline Plc
11.2.1 GlaxoSmithKline Plc Company Detail
11.2.2 GlaxoSmithKline Plc Business Overview
11.2.3 GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.2.4 GlaxoSmithKline Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2019-2024)
11.2.5 GlaxoSmithKline Plc Recent Development
11.3 Eidos Therapeutics
11.3.1 Eidos Therapeutics Company Detail
11.3.2 Eidos Therapeutics Business Overview
11.3.3 Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.3.4 Eidos Therapeutics Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2019-2024)
11.3.5 Eidos Therapeutics Recent Development
11.4 Ionis Pharmaceuticals, Inc
11.4.1 Ionis Pharmaceuticals, Inc Company Detail
11.4.2 Ionis Pharmaceuticals, Inc Business Overview
11.4.3 Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.4.4 Ionis Pharmaceuticals, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2019-2024)
11.4.5 Ionis Pharmaceuticals, Inc Recent Development
11.5 Alnylam Pharmaceuticals
11.5.1 Alnylam Pharmaceuticals Company Detail
11.5.2 Alnylam Pharmaceuticals Business Overview
11.5.3 Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.5.4 Alnylam Pharmaceuticals Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2019-2024)
11.5.5 Alnylam Pharmaceuticals Recent Development
11.6 Prothena Corporation Plc
11.6.1 Prothena Corporation Plc Company Detail
11.6.2 Prothena Corporation Plc Business Overview
11.6.3 Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.6.4 Prothena Corporation Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2019-2024)
11.6.5 Prothena Corporation Plc Recent Development
11.7 Intellia Therapeutics, Inc
11.7.1 Intellia Therapeutics, Inc Company Detail
11.7.2 Intellia Therapeutics, Inc Business Overview
11.7.3 Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.7.4 Intellia Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2019-2024)
11.7.5 Intellia Therapeutics, Inc Recent Development
11.8 Corino Therapeutics, Inc
11.8.1 Corino Therapeutics, Inc Company Detail
11.8.2 Corino Therapeutics, Inc Business Overview
11.8.3 Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Introduction
11.8.4 Corino Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2019-2024)
11.8.5 Corino Therapeutics, Inc Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Transthyretin Stabilizers
Table 3. Key Players of Nonsteroidal Anti-inflammatory Drugs (NSAID)
Table 4. Key Players of RNAi Therapy
Table 5. Key Players of Others
Table 6. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Region (2019-2024)
Table 10. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Region (2025-2030)
Table 12. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Trends
Table 13. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Drivers
Table 14. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Challenges
Table 15. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Restraints
Table 16. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Players (2019-2024)
Table 18. Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment as of 2023)
Table 19. Ranking of Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product Solution and Service
Table 23. Date of Enter into Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Type (2019-2024)
Table 27. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Type (2025-2030)
Table 29. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Application (2019-2024)
Table 31. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue Market Share by Application (2025-2030)
Table 33. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size by Country (2025-2030) & (US$ Million)
Table 48. Pfizer Inc Company Detail
Table 49. Pfizer Inc Business Overview
Table 50. Pfizer Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
Table 51. Pfizer Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2019-2024) & (US$ Million)
Table 52. Pfizer Inc Recent Development
Table 53. GlaxoSmithKline Plc Company Detail
Table 54. GlaxoSmithKline Plc Business Overview
Table 55. GlaxoSmithKline Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
Table 56. GlaxoSmithKline Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2019-2024) & (US$ Million)
Table 57. GlaxoSmithKline Plc Recent Development
Table 58. Eidos Therapeutics Company Detail
Table 59. Eidos Therapeutics Business Overview
Table 60. Eidos Therapeutics Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
Table 61. Eidos Therapeutics Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2019-2024) & (US$ Million)
Table 62. Eidos Therapeutics Recent Development
Table 63. Ionis Pharmaceuticals, Inc Company Detail
Table 64. Ionis Pharmaceuticals, Inc Business Overview
Table 65. Ionis Pharmaceuticals, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
Table 66. Ionis Pharmaceuticals, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2019-2024) & (US$ Million)
Table 67. Ionis Pharmaceuticals, Inc Recent Development
Table 68. Alnylam Pharmaceuticals Company Detail
Table 69. Alnylam Pharmaceuticals Business Overview
Table 70. Alnylam Pharmaceuticals Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
Table 71. Alnylam Pharmaceuticals Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2019-2024) & (US$ Million)
Table 72. Alnylam Pharmaceuticals Recent Development
Table 73. Prothena Corporation Plc Company Detail
Table 74. Prothena Corporation Plc Business Overview
Table 75. Prothena Corporation Plc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
Table 76. Prothena Corporation Plc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2019-2024) & (US$ Million)
Table 77. Prothena Corporation Plc Recent Development
Table 78. Intellia Therapeutics, Inc Company Detail
Table 79. Intellia Therapeutics, Inc Business Overview
Table 80. Intellia Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
Table 81. Intellia Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2019-2024) & (US$ Million)
Table 82. Intellia Therapeutics, Inc Recent Development
Table 83. Corino Therapeutics, Inc Company Detail
Table 84. Corino Therapeutics, Inc Business Overview
Table 85. Corino Therapeutics, Inc Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Product
Table 86. Corino Therapeutics, Inc Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2019-2024) & (US$ Million)
Table 87. Corino Therapeutics, Inc Recent Development
Table 88. Research Programs/Design for This Report
Table 89. Key Data Information from Secondary Sources
Table 90. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Type: 2023 VS 2030
Figure 3. Transthyretin Stabilizers Features
Figure 4. Nonsteroidal Anti-inflammatory Drugs (NSAID) Features
Figure 5. RNAi Therapy Features
Figure 6. Others Features
Figure 7. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Application: 2023 VS 2030
Figure 9. Hereditary Transthyretin Amyloidosis (hATTR) Case Studies
Figure 10. Wild Type Transthyretin Amyloidosis (wtATTR) Case Studies
Figure 11. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Report Years Considered
Figure 12. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Region: 2023 VS 2030
Figure 15. Global Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Players in 2023
Figure 16. Global Top Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Revenue in 2023
Figure 18. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Country (2019-2030)
Figure 20. United States Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Country (2019-2030)
Figure 24. Germany Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Region (2019-2030)
Figure 32. China Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Country (2019-2030)
Figure 40. Mexico Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Share by Country (2019-2030)
Figure 44. Turkey Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Pfizer Inc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2019-2024)
Figure 47. GlaxoSmithKline Plc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2019-2024)
Figure 48. Eidos Therapeutics Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2019-2024)
Figure 49. Ionis Pharmaceuticals, Inc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2019-2024)
Figure 50. Alnylam Pharmaceuticals Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2019-2024)
Figure 51. Prothena Corporation Plc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2019-2024)
Figure 52. Intellia Therapeutics, Inc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2019-2024)
Figure 53. Corino Therapeutics, Inc Revenue Growth Rate in Transthyretin amyloid cardiomyopathy (ATTR-CM) Treatment Business (2019-2024)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies